Detailed Information

Cited 353 time in webofscience Cited 390 time in scopus
Metadata Downloads

Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinomaopen access

Authors
Lee, Joon HyeokLee, Jeong-HoonLim, Young-SukYeon, Jong EunSong, Tae-JinYu, Su JongGwak, Geum-YounKim, Kang MoKim, Yoon JunLee, Jae WonYoon, Jung-Hwan
Issue Date
Jun-2015
Publisher
W B SAUNDERS CO-ELSEVIER INC
Keywords
Liver Cancer; Clinical Trial; IL2; NK Cell
Citation
GASTROENTEROLOGY, v.148, no.7, pp 1383 - +
Indexed
SCI
SCIE
SCOPUS
Journal Title
GASTROENTEROLOGY
Volume
148
Number
7
Start Page
1383
End Page
+
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/7856
DOI
10.1053/j.gastro.2015.02.055
ISSN
0016-5085
1528-0012
Abstract
BACKGROUND & AIMS: No adjuvant therapy has been shown to extend the survival of patients with hepatocellular carcinoma (HCC) receiving curative treatment. We investigated whether injections of activated cytokine-induced killer (CIK) cells (CD3+/CD56+ and CD3+/CD56-T cells and CD3-/CD56+ natural killer cells) prolongs recurrence-free survival of patients after curative therapy for HCC. METHODS: We performed a multicenter, randomized, open-label, phase 3 trial of the efficacy and safety of adjuvant immunotherapy with activated CIK cells (created by incubation of patients' peripheral blood mononuclear cells with interleukin 2 and an antibody against CD3). The study included 230 patients with HCC treated by surgical resection, radiofrequency ablation, or percutaneous ethanol injection at university-affiliated hospitals in Korea. Patients were assigned randomly to receive immunotherapy (injection of 6.4 x 10(9) autologous CIK cells, 16 times during 60 weeks) or no adjuvant therapy (controls). The primary end point was recurrence-free survival; secondary end points included overall survival, cancer-specific survival, and safety. RESULTS: The median time of recurrence-free survival was 44.0 months in the immunotherapy group and 30.0 months in the control group (hazard ratio with immunotherapy, 0.63; 95% confidence interval [CI], 0.43-0.94; P = .010 by 1-sided log-rank test). Hazard ratios also were lower in the immunotherapy than in the control group for all-cause death (0.21; 95% CI, 0.06-0.75; P = .008) and cancer-related death (0.19; 95% CI, 0.04-0.87; P = .02). A significantly higher proportion of patients in the immunotherapy group than in the control group had an adverse event (62% vs 41%; P = .002), but the proportion of patients with serious adverse events did not differ significantly between groups (7.8% vs 3.5%; P = .15). CONCLUSIONS: In patients who underwent curative treatment for HCC, adjuvant immunotherapy with activated CIK cells increased recurrence-free and overall survival. ClinicalTrials.gov number: NCT00699816.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Hepato-Biliary-Pancreatic Surgery > 1. Journal Articles
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yeon, Jong Eun photo

Yeon, Jong Eun
Guro Hospital (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE